MIRA
INFORM REPORT
|
Report Date : |
27.03.2008 |
IDENTIFICATION
DETAILS
|
Name : |
RELISH PHARMACEUTICALS LIMITED |
|
|
|
|
Registered Office : |
1-2 Moon Light 3rd Floor, Opposite Gurukul Drive in Road,
Memnagar, Ahmedabad – 380 052, Gujarat |
|
|
|
|
Country : |
India |
|
|
|
|
Financials (as on) : |
31.3.2005 |
|
|
|
|
Date of Incorporation : |
04.03.1993 |
|
|
|
|
Com. Reg. No.: |
04-19079 |
|
|
|
|
CIN No.: [Company
Identification No.] |
L24231GJ1993PLC019079 |
|
|
|
|
TAN No.: [Tax
Deduction & Collection Account No.] |
AHMR03876F |
|
|
|
|
PAN No.: [Permanent
Account No.] |
AAACR5476N |
|
|
|
|
Legal Form : |
A closely held Public Limited Liability Company. |
|
|
|
|
Line of Business : |
Manufacturer of Pharmaceutical Products. |
RATING &
COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
Maximum Credit Limit : |
USD 27000 |
|
|
|
|
Status : |
Moderate |
|
|
|
|
Payment Behaviour : |
Slow |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is an old and established company having moderate track. It
has not filed any financials after 31.03.2005 with the Government department.
As per last available financials, the company had huge accumulated losses.
Payments are reported as slow and delayed. The company can be considered for small to mediocre business dealings
on safe and secured terms. |
LOCATIONS
|
Registered Office : |
1-2 Moon Light 3rd Floor, Opposite Gurukul Drive in Road,
Memnagar, Ahmedabad – 380 052, Gujarat , India |
|
Tel. No.: |
91-79-27447247 / 66522247 |
|
Fax No.: |
91-79-26858945 / 27498515 |
|
E-Mail : |
|
|
Website : |
|
|
|
|
|
Factory : |
795, Rakanpur, Sola – Santej, Taluka, Kalol (NG), District,
Gandhinagar, India |
|
Tel. No.: |
91-2764-286317 |
DIRECTORS
|
Name : |
Mr. Mihir M Patel |
|
Designation : |
Director Cum Chairman |
|
Address : |
1/C –D, Shyam Gokul Flats, Near Vijay Char Rasta , Drive In Road,
Navrang Pura, Ahmedabad – 380 009, Gujarat, India |
|
Date of Birth/Age : |
01.03.1967 |
|
Date of Appointment : |
13.09.1993 |
|
|
|
|
Name : |
Mrs. Ridhi M Patel |
|
Designation : |
Director |
|
Address : |
1/C –D, Shyam Gokul Flats, Near Vijay Char Rasta , Drive In Road,
Navrang Pura, Ahmedabad – 380 009, Gujarat, India |
|
Date of Birth/Age : |
01.06.1972 |
|
Date of Appointment : |
13.09.1993 |
|
|
|
|
Name : |
Mr. Ramesh Desai |
|
Designation : |
Director |
|
Address : |
1/C –D, Shyam Gokul Flats, Near Vijay Char Rasta , Drive In Road,
Navrang Pura, Ahmedabad – 380 009, Gujarat, India |
|
Date of Birth/Age : |
01.06.1972 |
|
Date of Appointment : |
01.11.2002 |
BUSINESS DETAILS
|
Line of Business : |
Manufacturer of Pharmaceutical Products. |
|
|
|
|
Products : |
· Anti Biotics (Penicillin ) · Anti Biotics (Cephalosporin) · Anti Biotics · Macrolides · Quinolones · Anti Bacterial · Anti Fungal · Anti Malarial · Anti Viral · Anti Protozoal · Anti Anthelmintic · Sedative and Tranquilliser · Anti Depressant · Anti Manic · Anti Emetic · Anti Ulcer · Beta Blockers · Diuretics · Analgesic · Analgesic (NASID) · Muscle Relaxants · Anti Tuberculosis · Vitamin Products · Anti Allergics · Corticosteroids · Hyper and Hypoglycamics |
GENERAL
INFORMATION
|
Bankers : |
Union Bank of India Industrial
Finance Branch, C U Shah Chambers , Ashram Road, Ahmedabad – 380 014,
Gujarat, India |
|
|
|
|
Banking
Relations : |
Satisfactory |
|
|
|
|
Auditors : |
|
|
Name : |
· Doctor and Patel Chartered Accountants Maninagar, Ahmedabad – 380 001, Gujarat,
India · Shrelk R Vaishnav Chartered Accountants Ahmedabad – 380 001, Gujarat, India |
|
|
|
|
Associates/Subsidiaries : |
Nil |
CAPITAL STRUCTURE
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
12000000 |
Equity Shares |
Rs. 10/-
each |
Rs.120.000 millions |
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
8986200 |
Equity Shares |
Rs. 10/-
each |
Rs.89.862
millions |
FINANCIAL DATA
[all figures are in Rupees Millions]
ABRIDGED BALANCE
SHEET
|
SOURCES OF FUNDS |
31.03.2005 |
31.03.2004 |
31.03.2003 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
89.862 |
89.862 |
89.862 |
|
|
2] Share Application Money |
0.000 |
0.000 |
0.000 |
|
|
3] Reserves & Surplus |
0.000 |
0.000 |
0.000 |
|
|
4] (Accumulated Losses) |
[83.168] |
[74.759] |
[65.816] |
|
|
NETWORTH |
6.694 |
15.103 |
24.046 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
76.142 |
73.827 |
70.239 |
|
|
2] Unsecured Loans |
2.676 |
2.330 |
3.219 |
|
|
TOTAL BORROWING |
78.818 |
76.157 |
73.458 |
|
|
DEFERRED TAX LIABILITIES |
9.936 |
9.937 |
9.937 |
|
|
|
|
|
|
|
|
TOTAL |
95.448 |
101.197 |
107.441 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
47.035 |
53.469 |
60.185 |
|
|
Capital work-in-progress |
0.457 |
0.457 |
0.000 |
|
|
|
|
|
|
|
|
INVESTMENT |
0.000 |
0.000 |
0.000 |
|
|
DEFERREX TAX ASSETS |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
5.879
|
8.487 |
0.000 |
|
|
Sundry Debtors |
49.130
|
57.914 |
0.000 |
|
|
Cash & Bank Balances |
0.464
|
0.249 |
0.000 |
|
|
Other Current Assets |
0.000
|
0.000 |
64.035 |
|
|
Loans & Advances |
17.228
|
17.538 |
20.335 |
|
Total
Current Assets |
72.701
|
84.188 |
84.370 |
|
|
Less : CURRENT LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Current Liabilities |
16.756
|
35.838 |
36.858 |
|
|
Provisions |
7.989
|
1.079 |
0.810 |
|
Total
Current Liabilities |
24.745
|
36.917 |
37.668 |
|
|
Net Current Assets |
47.956
|
47.271 |
46.702 |
|
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
0.000 |
0.000 |
0.554 |
|
|
|
|
|
|
|
|
TOTAL |
95.448 |
101.197 |
107.441 |
|
KEY RATIOS
|
PARTICULARS |
|
31.03.2005 |
31.03.2004 |
31.03.2003 |
|
Debt Equity Ratio (Total Liability/Networth) |
|
15.47
|
7.48 |
4.62 |
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
2.94
|
2.28 |
2.24 |
LOCAL AGENCY
FURTHER INFORMATION
FORM 8:-
|
Name of the
company |
RELISH PHARMACEUTICALS LIMITED |
|
Presented By |
Shri Mihir Patel
, Managing Director |
|
1) Date and description
of instrument creating the change |
Hypothecation
(goods) agreement dated 13.02.1996 executed by the company in favour of Union
Bank of India (hereinafter referred to as the Bank) certified copy where of
is enclosed. |
|
2) Amount secured
by the charge/amount owing on the securities of charge |
Rs. 8.500
millions |
|
3) Short
particular of the property charged. If the property acquired is subject to
charge, date of the acquired of the property should be given |
All stocks of raw
materials viz, pharmaceuticals formulation and work in process , finished
goods i.e. tablets, Liquid, Injectables, etc. situated at 795 , Rakanpur,
Sola – Santej Road, Taluka, Kalol, District Mehsana and / or in transit both
present and future. |
|
4) Gist of the
terms and conditions and extent and operation of the charge. |
Repayable on demand , Interest @ 3% OPLR
subject to minimum 20.25% p.a including Interest tax payable with quarterly
rests, Margin : 25% |
|
5) Name and
Address and description of the person entitled to the charge. |
Union Bank of India Industrial Finance Branch, C U Shah
Chambers , Ashram Road, Ahmedabad – 380 014 |
|
6) Date and brief description of instrument
modifying the charge |
Extension of
charge of hypothecation dated 13.02.1996 |
|
7) Particulars of
modifications specifying the terms and conditions or the extent of operations
of the charge in which modification is made and the details of the
modification. |
By supplemental
instrument of hypothecation of goods dated 13.02.1996 referred in column 6
above the charge dated 13.02.1996 created for Rs. 8.500 millions has now been
extended to secure the various limits viz, cash , credit (book debts) of Rs.
1.500 millions and Imp Inl , L/C (sight) of Rs. 5.000 millions making
aggregate charge of Rs. 15.000 millions on the stock of goods. |
WEBSITE DETAILS:
Company Profile:
Subject is a public limited company with a global perspective,
manufacturing, exporting and marketing in both domestic and international
markets. Today, buyers in Australia, United Kingdom, Kenya, Uganda, Mauritius,
Sri Lanka, Republic of Yemen and Nigeria depend upon subject In the vast
Pharmaceuticals Limited for quality qualification.
Indian Pharmaceuticals market comprising over 20,000 manufacturing units,
Subject has earned itself a formidable reputation. Expertise in Research and
Development, Formulation manufacturing, latest quality movement and in-depth
insight into the Indian and international Pharmaceuticals markets, Subject has
made unrivaled progress. Current growth rate of the company has exceeded 79%!
Subject has assisted in the development and manufacture of a wide
variety of drugs and dosage forms and potency variations for many prestigious
pharmaceuticals companies around the world..
The Team
The secrete of their success..
Lies not so much in the state of the science manufacturing facilities as
in the "State-of-the-mind" of their people.
Highly experienced, qualified, dedicated professionals continuously
updated with the latest technical advances, manufacturing innovations and
product standards in the field.
A reason of subject become the choice
of people is they know value of production efficiency, safety, high output,
economy, quality, speed and course commitment to schedules.
Rely on Relish to..
Understand the individual manufacturing requirements.
·
Provide total resource to extend the company's
capabilities. 
· Meet the goals of a timely entry in to the market.
· Use outsourcing as a strategic move in the product life cycle planning.
· Gain a greater economic edge in a highly competitive market.
· Develop new dosage forms and manufacturing procedures.
· Their strength is providing total customer satisfaction by delivering superior quality products through cutting edge technology and the best possible services.
Mission and Vision
Their Mission: To be diversified Business Corporation to achieve leadership by exceeding customer expectation in domestic as well as overseas markets.
Their Vision: To attain financial strength through ever growing
profitability to attain excellence while achieving "Supreme customer
satisfaction" to attain the global recognition for the corporation.
Core Value: To focus on customer's need and fulfill their expectations.
To provide services and products of the most superior quality.
To seek consistent improvement innovation and excellence in their performance.
To create working environments which helps committed people to achieve their
fullest potential. Provide them ample opportunity to grow.
To develop image where shareholders, employees, suppliers and customers take pride in being associated with them.
Commit to the highest standards of ethics and integrity.
Quality Policy
Their credentials and experience in networking with the world absorb the
latest technological and product innovations has been the greatest indicator of
their success
Their flexibility and attention to the specialized individual
manufacturing requirements ensures that their services greatly enhance the
business opportunities of their clients
Subject has been certified GMP and WHO GMP approved status given by
Gujarat State Food and Drug Control Administration as per revised schedule
"M". At their certified facilties, Qualified personnels perform full
in house quality control testing.
Each process of manufacturing and all the facilities are under strict
accountability. Control and conform to cGMP standards. Extensive aseptic
validation of wide range of filing processes as well as of new existing
equipment is routine.
Manufacturing
The long-term goal of Subject is to become a pharmaceutical company driven by research. The company also takes all most care to ensure that a safe formulation of medicine being manufactured is prepared by method and process. Prescribe with international specifications.
With four different manufacturing divisions namely tablets (General and Beta Lactum) Capsules (General and Beta Lactum), Liquid and small volume parental the company has all manufacturing capabilities.
With the prime focus on customer satisfaction, continuous efforts are made to offer solutions that give an extra advantage to the customer
Their endeavour to walk an extra milage by providing their customers with alternate solutions, customized products and packaging has resulted in expanding their business horizons and proximity to the lives of people. They remain focused on developing application related derivatives of existing products as well as newer product solutions
R and D
Driven by the belief that futuristic products are the elixir of growth,
a dedicated and talented team of Research and Development professionals remain
focused on exploring new areas of core competence.
A strong desire for continuous innovation forms the bedrock of the efforts
of this dedicated and talented team. Perseverance and Passion for new ideas are
the driving forces, which leverage the efforts to develop new product
Solutions, Processes and Applications.
A strong harmony between R and D, Production and Marketing team aids in
fine tuning production processes to make them more efficient and environment
friendly.
Customer profile
Their customer profile includes leading Manufacturers like Cadila
Healthcare Limited (Zydus), Intas Pharmaceuticals Limited, Cadila Pharmaceuticals
Limited, Makers Laboratories Limited, Agenta Pharma Limited etc.
Globalisation is a thrust area at their end which is evident from their
continuous efforts to enhance their International Business, which currently
accounts for one third of their business.
Subject has assisted in the development and manufacture of a wide
variety of drugs and dosage forms and potency variations for many prestigious
pharmaceuticals companies around the world..
Products:
· Ampicillin Tablets 250 mg. / 500 mg.
· Ampicillin Capsules 250 mg. / 500 mg.
· Ampicillin Oral Suspension 125 mg/ 5ml and 250 mg / 5 ml - 60 ml / 100 ml
· Ampicillin 250 mg. and Cloxacillin 250 mg. Capsules
· Ampicillin 125 mg. and Cloxacillin 125 mg Oral Suspension 60 ml / 100 ml
· Amoxicillin Tablets 250 mg. / 500 mg.
· Amoxicillin Capsules 250 mg. / 500 mg.
· Amoxicillin Oral Suspension 125 mg/ 5ml and 250 mg / 5 ml - 60 ml / 100 ml
· Amoxicillin 250 mg. and Cloxacillin 250 mg. Capsules
· Amoxicillin 125 mg. and Cloxacillin 125 mg Oral Suspension 60 ml / 100 ml
· Amoxicillin 250 mg. / 500 mg. and Clavulanic Acid 125 mg. Tablets
· Amoxicillin 125 mg. and Clavulanic Acid 31. 25 mg Oral Suspension 60 ml / 100 ml
· Cloxacillin Capsules 250 mg. / 500 mg.
· Cephalexine Capsules 250 mg. / 500 mg.
· Cephalexine Oral Suspension 125 mg / 5 ml - 30 ml / 40 ml
· Cefadroxil Tablets 250 mg. / 500 mg.
· Cefadroxil Oral Suspension 125 mg. / 5ml - 30 ml / 40 ml
· Cefuroxime Axetil Tablets 250 mg. / 500 mg.
· Cefuroxime Axetil Oral Suspension 125 mg / 5 ml - 30 ml
· Cefixime Trihydrate Tablets 100 mg. / 200 mg. / 400 mg.
· Cefixime Trihydrate Oral Suspension 100 mg/ 5ml - 30 ml
· Cefpodoxine Proxetil Tablets 100 mg. / 200 mg.
· Cefpodoxine Proxetil Oral Suspension 50 mg / 5 ml - 30 ml
· Chloramphenicol Capsules 250 mg. / 500 mg.
· Chloramphenicol Oral Suspension 125 mg / 5 ml - 60 ml
· Doxycycline Hyclate Tablets 100 mg.
· Doxycycline Capsules 100 mg.
· Amikacin Injection - 100 mg. / 250 mg. / 500 mg.
· Gentamicin Injection 40 mg / ml - 2 ml / 10 ml / 20 ml / 30 ml
· Erythromycin Estolate Tablets 250 mg. / 500 mg.
· Erythromycin Estolate Oral Suspension 125 mg / 5ml - 60 ml / 100 ml
· Erythromycin Stearate Tablets 250 mg. / 500 mg.
· Clarithromycin Tablets 250 mg. / 500 mg.
· Roxithromycin Tablets 150 mg. / 300 mg.
· Azithromycin Tablets 250 mg. / 500 mg. / 1 gm.
· Azithromycin Oral Suspension 100 mg / 5 ml - 15 ml
· Ciprofloxacin Tablets 250 mg. / 500 mg. / 750 mg.
· Gatifloxacin Tablets 200 mg. / 400 mg.
· Levofloxacin Tablets 250 mg. / 500 mg.
· Norfloxacin Tablets 400 mg.
· Pefloxacin Tablets 400 mg.
· Ofloxacin Tablets 200 mg. / 400 mg.
· Co - Trimoxazole Tablets 120 mg. / 480 mg. / 960 mg.
· Co - Trimoxazole Oral Suspension 240 mg / 5 ml - 60 ml / 100 ml
· Griseofulvin Tablets 125 mg. / 250 mg. / 500 mg.
· Ketoconazole Tablets 200 mg.
· Fluconazole Tablets 150 mg.
· Artesunate Tablets 50 mg.
· Artemether Injection 80 mg / ml - 1 ml Amp.
· a - b Arteether Injection 75 mg / ml - 2 ml Amp.
· Chloroquine Tablets 250 mg. / 500 mg.
· Chloroquine Syrup 50 mg / 5 ml - 60 ml / 100 ml
· Chloroquine Injection 50 ml / ml
· Primaquine Tablets 7.5 mg. / 15 mg.
· Pyrimethamine Tablets 25 mg.
· Quinine Sulphate Tablets 100 mg. / 300 mg.
· Quinine Sulphate Oral Suspension 100 mg / 5 ml - 60 ml / 100 ml
· Quinine Dihydrochloride Injection 300 mg / ml - 2 ml Amp.
· Sulphadoxine 500 mg. and Pyrimethamine 25 mg. Tablets
Anti Viral
· Acyclovir Tablets 200 mg. / 400 mg. / 800 mg.
· Lamivudine Tablets 100 mg. / 150 mg.
· Lamivudine Syrup 50mg / 5ml
· Zidovudine Capsules 100 mg. / 300 mg.
· Lamivudine 150 mg. and Zidovudine 300 mg. Tablets
· Stavudine Capsules 30 mg. / 40 mg.
· Lamivudine 150 mg. and Stavudine 30 mg Tablets
· Lamivudine 150 mg. and Stavudine 40 mg Tablets
· Nevirapine Tablets 200 mg.
· Lamivudine 150 mg. Stavudine 30 mg. and Nevirapine 200 mg. Tablets
· Lamivudine 150 mg. Stavudine 40 mg. and Nevirapine 200 mg. Tablets
· Indinavir Sulphate Capsules 200 mg. / 400 mg.
· Efavirenz Tablets 200 mg.
· Nelfinavir Tablets 250 mg.
· Ritonavir Capsules 250 mg.
· Flurazolidone Tablets 100 mg.
· Metronidazole Tablets 200 mg. / 250 mg. / 400 mg.
· Metronidazole Oral Suspension 200 mg. / 5 ml - 60 ml / 100 ml
· Ornidazole Tablets 500 mg.
· Secnidazole Tablets 500 mg. / 1Gm.
· Tinidazole Tablets 300 mg. / 500 mg.
Anti Anthelmintic
· Albendazole Tablets 200 mg. / 400 mg.
· Albendazole Oral Suspension 200 mg. / 5 ml
· Diethyl Carbamazine Citrate Tablets 50 mg. / 100 mg.
· Ivermectin Tablets 3 mg. / 6 mg.
· Levamisole Tablets 50 mg. / 150 mg.
· Mebendazole Tablets 100 mg. / 500 mg.
· Mebendazole Oral Suspension 100 mg. / 5 ml
· Praziquantel Tablets 600 mg.
· Alprazolam Tablets 0.25 mg. / 0.5 mg. / 1 mg. / 1.5 mg.
· Buspirone HCl Tablets 5 mg. / 10 mg.
· Chlordiazepoxide Tablets 10 mg.
· Diazepam Tablets 5 mg. / 10 mg.
· Diazepam Injection 10 mg / 2 ml
· Lorazepam Tablets 1 mg. / 2 mg.
· Lorazepam Injection 2 mg / ml - 2 ml Amp.
· Nitrazepam Tablets 5 mg. / 10 mg.
·
Amitriptyline Tablets 10 mg. / 25 mg. / 75 mg.
· Clomipramine Tablets 10 mg. /25 mg. / 50 mg.
· Imipramine Tablets 25 mg.
· Fluoxetine HCl Capsules 20 mg.
· Trimipramine Tablets 10 mg. / 25 mg.
·
Chlorpromazine Tablets 10 mg. / 25 mg. / 50 mg. / 100
mg.
· Haloperidol Tablets 5 mg. / 10 mg.
· Haloperidol Injection 5 mg / ml - 1 ml Amp.
· Olanzepine Tablets 2.5 mg. / 5 mg. / 7.5 mg. / 10 mg.
· Resperidone Tablets 1 mg. /2 mg. /3 mg. / 4 mg.
· Thioridazine Tablets 25 mg. / 50 mg. / 100 mg.
·
Domperidone Tablets 10 mg.
· Metoclopramide Tablets 5 mg. / 10 mg.
· Metoclopramide Injection 5 mg / ml - 2 ml Amp.
· Ondansetron Tablets 4 mg. / 8 mg.
· Ondansetron Injection 2 mg / ml - 2 ml Amp.
· Promethazine HCl Tablets 25 mg.
· Promethazine Oral Solution 5 mg / 5 ml
· Prochlorperazine Maleate Tablets 5 mg.
· Prochlorperazine Maleate Injection 12.5 mg / ml - 1 ml Amp.
· Cimitidine Tablets 200 mg. / 400 mg.
· Esomeprazole Tablets 20 mg. /40 mg.
· Famotidine Tablets 20 mg. / 40 mg.
· Lansoprazole Capsule 15 mg. / 30 mg.
· Omeprazole Capsule 20 mg.
· Pantoprazole Tablets 20 mg. / 40 mg.
· Ranitidine Tablets 150 mg. / 300 mg.
· Ranitidine Injection 25 mg / ml - 2 ml Amp.
· Sucralfate Tablets 1 gm.
· Atenolol Tablets 50 mg. / 100 mg.
· Propranolol Tablets 10 mg. / 40 mg.
·
Acetazolamide Tablets 250 mg.
· Amiloride Tablets 5 mg.
· Frusemide Tablets 40 mg.
· Frusemide Injection 20 mg / 2 ml - 2 ml Amp.
· Hydrochlorothiazide Tablets 50 mg.
·
Buprenorphine Tablets 0.2 mg.
· Buprenorphine Injection 0.3 mg / ml - 2 ml Amp.
· Dextropropoxyphene Capsules 65 mg.
· Tramadol Tablets 50 mg. / 100 mg.
· Tramadol Injection 50 mg / ml - 1 ml Amp.
· Analgin Tablets 500 mg. (Metamizol)
· Analgin Injection 0.5 gm / ml
· Aspirin Tablets 100 mg. / 300 mg. / 500 mg.
· Carbamazepine Tablets 100 mg. / 200 mg. / 400 mg.
· Diclofenac Sodium Tablets 50 mg. / 100 mg.
· Diclofenac Sodium Injection 75 mg / ml - 3 ml Amp.
· Diclofenac Potassium Tablets 75 mg.
· Ibuprofen Tablets 200 mg. / 400 mg. / 600 mg.
· Ibuprofen Oral Suspension 100 mg / 5 ml - 60 ml / 100 ml
· Indomethacin Tablets 25 mg.
· Indomethacin Capsules 25 mg.
· Mefenamic Acid Tablets 250 mg. / 500 mg.
· Nimesulide Tablets 100 mg.
· Nimesulide Oral Suspension 50 mg / 5 ml
· Nimesulide Injection 25 mg / ml - 2 ml Amp.
· Paracetamol Tablets 100 mg. / 500 mg. / 650 mg.
· Paracetamol Oral Suspension 125 mg / 5 ml - 60 ml / 100 ml
· Paracetamol Injection
· Rofecoxib Tablets 25 mg. / 50 mg.
· Valdecoxib Tablets 10 mg. / 20 mg.
Muscle Relaxants
· Dicyclomine HCl Tablets 20 mg.
· Dicyclomine Injection 10 mg / ml - 2 ml Amp.
· Drotaverine Tablets 40 mg. / 80 mg.
· Drotaverine Injection 40 mg / 2 ml - 2 ml Amp.
· Orphenadrine Tablets 35 mg.
· Tizanidine Tablets 2 mg. / 4 mg.
· Ethambutol Tablets 200 mg. / 400 mg. / 600 mg. / 800 mg.
· Ethambutol with Isoniazid Tablets
· Isoniazid Tablets 100 mg. / 300 mg.
· Pyrazinamide Tablets 500 mg. / 750 mg.
· Rifampicin Capsules 150 mg. / 300 mg. / 450 mg.
· Rifampicin Oral Suspension 100 mg / 5 ml - 60 ml
· Rifampicin with Isoniazid Capsules / Tablets
· Ascorbic Acid Tablets 100 mg. / 500 mg.
· Folic Acid Tablets 5 mg.
· Pyridoxine HCl Tablets
· Thiamine HCl Tablets
· Ferrous Sulphate with Folic Acid Tablets
· Multivitamin Tablets / Syrups
· Vitamin B Complex Tablets / Injections
· Cetirizine Dihydrochloride Tablets 10 mg.
· Cetirizine Dihydrochloride Syrup 10 mg / 5ml - 60 ml
· Chlorpheniramine Maleate Tablets 4 mg.
· Chlorpheniramine Syrup 2 mg / 5 ml - 100 ml
· Diphenhydramine HCl Tablets 10 mg. / 25 mg.
· Diphenhydramine HCl Oral Solution - 100 ml
· Levocetirizine Dihydrochloride Tablets 5 mg.
· Pheniramine Maleate Tablets 25 mg. / 50 mg.
· Betamethasone Tablets 0.5 mg.
· Dexamethasone Tablets 0.5 mg. / 4 mg.
· Dexamethasone Injection 4 mg / ml - 2 ml / 10 ml / 20 ml / 30 ml
· Prednisone Tablets 50 mg.
· Prednisolone Tablets 5 mg. / 10 mg.
· Chlorpropamide Tablets 50 mg.
· Glibenclamide Tablets 5 mg.
· Glibenclamide with Metformin Tablets
· Gliclazide Tablets 30 mg. / 60 mg.
· Gliclazide with Metformin Tablets
· Glimepride Tablets 1 mg. / 2 mg. / 4 mg.
· Glipizide Tablets 5 mg. / 10 mg.
· Glipizide with Metformin Tablets
· Metformin Tablets 250 mg. / 500 mg. / 850 mg. / 1 gm.
·
Calcium Preparation
· Ophthalmic Preparation
· Expectorants and Anti Tussives
· Bronchodilators
· Antioxidants
· Iron Preparation
· Zinc Preparation
· All Veterinary Products
· All Cosmetics Products
CMT REPORT
(Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts, India Prisons Service,
Interpol, etc.
1] INFORMATION ON
DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE
GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE
RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.39.97 |
|
UK Pound |
1 |
Rs.79.53 |
|
Euro |
1 |
Rs.63.09 |
SCORE & RATING
EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
5 |
|
PAID-UP CAPITAL |
1~10 |
5 |
|
OPERATING SCALE |
1~10 |
2 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
6 |
|
--PROFITABILIRY |
1~10 |
--- |
|
--LIQUIDITY |
1~10 |
7 |
|
--LEVERAGE |
1~10 |
4 |
|
--RESERVES |
1~10 |
2 |
|
--CREDIT LINES |
1~10 |
1 |
|
--MARGINS |
-5~5 |
--- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
NO |
|
--AFFILIATION |
YES/NO |
YES |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
29 |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|